



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	327222	Activated B6 Plus
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Interclinical Laboratories Pty Ltd	
<b>Postal Address</b>	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	9/12/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Activated B6 Plus

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	10/12/2019
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support energy levels  
Helps convert (state food) into energy  
Maintain/support energy production  
Maintain/support healthy eye function  
Maintain/support eye health  
Maintain/support body mucous membrane health  
Maintain/support general health and wellbeing  
Maintain/support hair growth  
Maintain/support hair health  
Aid/assist nail growth  
Maintain/support nail health/strength/thickness  
Aid/assist/helps connective tissue production/formation  
Maintain/support healthy body tissues  
Aid/assist healthy red blood cell production  
Maintain/support red blood cell health  
Helps maintain/support haemoglobin formation/synthesis  
Maintain/support heart health

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Maintain/support immune system health  
Maintain/support healthy immune system function  
Maintain/support muscle function  
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)  
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency  
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)  
Maintain/support nerve conduction  
Aid/assist/helps synthesis of neurotransmitters  
Maintain/support nervous system health  
Maintain/support nervous system function  
Maintain/support skin health

#### Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to chronic fatigue syndrome.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible.  
[Contains vitamin B6].

#### Additional Product information

#### Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

#### Components

##### 1 . Formulation 1

**Dosage Form** Capsule, hard

**Route of Administration** Oral

#### Visual Identification

#### Active Ingredients

<b>pyridoxal 5-phosphate monohydrate</b>	<b>31.35 mg</b>
Equivalent: pyridoxine	20 mg
<b>pyridoxine hydrochloride</b>	<b>36.46 mg</b>
Equivalent: pyridoxine	30 mg
<b>riboflavin</b>	<b>500 microgram</b>
<b>thiamine nitrate</b>	<b>2 mg</b>

#### Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate  
colloidal anhydrous silica  
hypromellose  
magnesium stearate

# Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**microcrystalline cellulose**

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary